following a full submission:
relugolix, estradiol, norethisterone acetate tablets (Ryeqo®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
SMC restriction: for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.
Relugolix, estradiol, norethisterone acetate tablets (Ryeqo®), compared with placebo, significantly reduced menstrual blood loss volume in patients with uterine fibroids and heavy menstrual bleeding.
Medicine details
- Medicine name:
- relugolix/estradiol/norethisterone acetate (Ryeqo)
- SMC ID:
- SMC2442
- Indication:
For treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
- Pharmaceutical company
- Gedeon Richter UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 June 2022